Modus Therapeutics Holding AB (publ) (MODTX) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to today's live broadcast from Modus Therapeutics, where we have with us the company's CEO, John Öd, to comment on the book release communiqué that the company presented here this morning, on January 20, 2025. And as usual, you can, as a follower of this live broadcast, ask questions to John directly in the chat. We have actually already received some questions, but that's just asking questions, so let's make sure that John can answer them as soon as possible. But then I say welcome to John, first and foremost. Thank you, Martin. The end of the book came out here this morning. You describe it as a revolving year for Modus, characterized by groundbreaking clinical progress and an enhanced pipeline. I'm just thinking about how you see the ongoing year and the position of the company before 2025. I think it's positive. This year, after a capital acquisition, we made it possible for us to drive the latest integration forward in the preparation work towards the planned start of the study in Nysjuka with Anemi. It is a transition for the company that with its portfolio comes into phase 2, where we We are ready for our self-suggestion and now in phase one for anemia and chronic disease. I thought it would be possible to comment on the financial position of the company, especially liquidity. You have as a goal to secure funding for part 2 in the CKD Anemi study under 2025 and also to secure funding for the phase 2 program for sepsis. How do you think about that in the future? Yes, I think we are taking it step by step. Now we are focusing on the new disease indication and business development and research development on the sepsis side. So the focus right now is that liquidity should meet the chronic new disease indication. And there we have, as before, It's been cle...